

Yogesh S Jethava

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8013136/publications.pdf>

Version: 2024-02-01

49
papers

490
citations

840119

11
h-index

713013

21
g-index

50
all docs

50
docs citations

50
times ranked

959
citing authors

#	ARTICLE	IF	CITATIONS
1	Wearable Monitors Facilitate Exercise in Adult and Pediatric Stem Cell Transplant. Exercise and Sport Sciences Reviews, 2021, 49, 205-212.	1.6	1
2	Case Studies in Physiology: Untangling the cause of hypoxemia in a patient with obesity with acute leukemia. Journal of Applied Physiology, 2021, 131, 788-793.	1.2	4
3	Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. Journal of the National Cancer Institute, 2020, 112, 507-515.	3.0	33
4	Minimal residual disease in multiple myeloma: are we there yet?. International Journal of Hematologic Oncology, 2020, 9, IJH29.	0.7	0
5	Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 8-9.	0.6	26
6	Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma. Blood, 2019, 134, 3059-3059.	0.6	1
7	Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma. Blood, 2019, 134, 5538-5538.	0.6	0
8	Approach to a patient with cardiac amyloidosis. Journal of Geriatric Cardiology, 2019, 16, 567-574.	0.2	7
9	Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology, 2018, 23, 17-24.	0.7	45
10	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1163-1171.	2.0	105
11	Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. International Journal of Molecular Sciences, 2018, 19, 3621.	1.8	17
12	Primary CNS high-grade B-cell lymphoma, with rearrangements of MYC and BCL6 : a case report. Blood Research, 2018, 53, 87.	0.5	0
13	Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. Journal of Clinical Investigation, 2018, 128, 2877-2893.	3.9	61
14	Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 47-56.	0.6	7
15	Cytomegalovirus appendicitis after hematopoietic stem cell transplantation. Transplant Infectious Disease, 2017, 19, e12747.	0.7	4
16	Drug Combinations with Transplantation for Myeloma. New England Journal of Medicine, 2017, 377, 91-94.	13.9	1
17	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical Cancer Research, 2017, 23, 2665-2672.	3.2	13
18	A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy. Journal of Oncology Pharmacy Practice, 2017, 23, 552-556.	0.5	2

#	ARTICLE	IF	CITATIONS
19	Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma. Oncotarget, 2017, 8, 111213-111224.	0.8	35
20	Transplantation for Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 227-250.	0.2	2
21	Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML. Blood, 2016, 128, 3983-3983.	0.6	17
22	Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States. Blood, 2016, 128, 4782-4782.	0.6	0
23	Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis. Blood, 2016, 128, 5594-5594.	0.6	1
24	Fulminant onset of acute leukemia from normal hematopoiesis within 3Âmonths of follow up for multiple myeloma treated with total therapy protocols. Clinical Case Reports (discontinued), 2015, 3, 183-192.	0.2	2
25	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 2015, 100, 1214-1221.	1.7	44
26	The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. Blood, 2015, 126, 1806-1806.	0.6	2
27	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. Blood, 2015, 126, 2979-2979.	0.6	2
28	Outcomes of primary plasmacytoma (PP) in United States (US).. Journal of Clinical Oncology, 2015, 33, 8597-8597.	0.8	0
29	Incidence and survival of chronic myelomonocytic leukemia (CMML) in the United States (US).. Journal of Clinical Oncology, 2015, 33, e18072-e18072.	0.8	0
30	Impact of total therapies on clinical outcome of myeloma stratified by risk and molecular subgroups.. Journal of Clinical Oncology, 2015, 33, 8586-8586.	0.8	0
31	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. Blood, 2015, 126, 3181-3181.	0.6	2
32	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. Blood, 2015, 126, 3182-3182.	0.6	1
33	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. Blood, 2015, 126, 4193-4193.	0.6	0
34	Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma. Blood, 2015, 126, 1777-1777.	0.6	23
35	Total Therapy 4 (TT4) for CEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rm (S-TT4 v L-TT4). Blood, 2014, 124, 1199-1199.	0.6	4
36	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2014, 124, 2128-2128.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. Blood, 2014, 124, 3409-3409.	0.6	5
38	Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. Blood, 2014, 124, 3418-3418.	0.6	3
39	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. Blood, 2014, 124, 4775-4775.	0.6	4
40	Trends in hospitalization outcomes of elderly patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia/myelodysplastic syndrome (AML/MDS).. Journal of Clinical Oncology, 2014, 32, 7044-7044.	0.8	2
41	Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP).. Journal of Clinical Oncology, 2014, 32, 8604-8604.	0.8	0
42	Survival outcomes of primary myelodysplastic syndrome in United States.. Journal of Clinical Oncology, 2014, 32, 7112-7112.	0.8	0
43	Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma. Blood, 2014, 124, 2079-2079.	0.6	0
44	Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt. Blood, 2014, 124, 2078-2078.	0.6	0
45	Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival. Blood, 2014, 124, 2012-2012.	0.6	0
46	PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients. Blood, 2014, 124, 3407-3407.	0.6	0
47	Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study. Blood, 2014, 124, 5770-5770.	0.6	0
48	Acquired Agranulocytosis and Factor XI Deficiency in Association With Thymoma. Journal of Clinical Oncology, 2011, 29, e604-e606.	0.8	13
49	A case of immune thrombocytopenic purpura secondary to endometriosis causing a pelvic haematoma. BMJ Case Reports, 2011, 2011, bcr0920103329-bcr0920103329.	0.2	0